Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | DRD2 | P14416 | 6/20 | 0.50 |
| ▸ | DRD3 | P35462 | 6/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | PER2 | O15055 | 1/20 | 0.39 |
| ▸ | CRY2 | Q49AN0 | 1/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5539716 | 0.79 | KMT2A (0.54) | MEN1KMT2ADRD3KCNH2HDAC1 | |
| SCHEMBL8393737 | 0.76 | RAB9A (0.64) | RAB9AMEN1NPC1KMT2ADRD2 | |
| SCHEMBL28798920 | 0.75 | TMEM97 (0.36) | RAB9AMEN1NPC1KMT2AHSD11B1 | |
| SCHEMBL14698020 | 0.73 | DRD2 (0.65) | RAB9AMEN1NPC1KMT2ADRD2 | |
| SCHEMBL610584 | 0.71 | NPC1 (1.00) | RAB9AMEN1NPC1KMT2ADRD2 | |
| SCHEMBL5544692 | 0.71 | CHRM3 (0.53) | DRD2DRD3 | |
| SCHEMBL6226262 | 0.70 | DRD2 (0.65) | RAB9AMEN1NPC1KMT2ADRD2 | |
| SCHEMBL5659037 | 0.70 | DRD2 (0.65) | RAB9AMEN1NPC1KMT2ADRD2 | |
| SCHEMBL3582057 | 0.70 | KMT2A (0.61) | RAB9AMEN1NPC1KMT2ADRD2 | |
| SCHEMBL23469574 | 0.70 | RAB9A (0.55) | RAB9AMEN1NPC1KMT2ADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | RAB9A 2824/4885MEN1 3295/4885NPC1 2404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.